← Cannabis Bioscience International Holdings, Inc. (CBIH) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Cannabis Bioscience International Holdings, Inc. (CBIH)
Services-Commercial Physical & Biological Research · market cap $2M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
14
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Oral Cannabis Extract | Phase 2 | Psoriasis Vulgaris |
| THC | Phase 2 | THC |
| Cannabis | Phase 2 | Fibromyalgia |
| Cannabidiol (246mg press pill) | Phase 2 | Memory |
| THC/CBD | Phase 3 | Back Pain |
| Full-spectrum CBD oil 100 mg/mL | Phase 2 | Major Depressive Disorder (MDD) |
| Mild dose cannabis | Phase 2 | Neuropathic Pain |
| THC Cannabis | Phase 2 | HIV |
| Epidiolex | Phase 2 | Autism |
| Experimental: Full-spectrum CBG oil 30 mg/mL | Phase 2 | Attention-Deficit/Hyperactivity Disorder (ADHD) |
| Cannabidiol oral solution | Phase 3 | Early Psychosis |
| CBD/THC | Phase 2 | Essential Tremor |
| Psilocybin combined with Psychotherapy | Phase 2 | Cannabis Use Disorder, Moderate |
| Cannabidiol (CBD) 800 mg | Phase 2 | Tobacco Use Disorder |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CBIH (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 14 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.